Neuroprotection for oxaliplatin-induced neurotoxicity: What happened to objective assessment?

Journal of Clinical Oncology

Volumn 29, Issue 18, 2011, Pages

  Park, Susanna B ^a   Goldstein, David ^b   Lin, Cindy S Y ^c   Krishnan, Arun V ^c   Friedlander, Michael L ^b   Kiernan, Matthew C ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b PRINCE OF WALES HOSPITAL   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CALCIUM; MAGNESIUM; OXALIPLATIN; PLACEBO;

CANCER CHEMOTHERAPY; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; COLORECTAL CANCER; CONVALESCENCE; DISEASE SEVERITY; DRUG EFFICACY; FOLLOW UP; HUMAN; LETTER; NERVE INJURY; NEUROPROTECTION; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; STANDARDIZATION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, ALKYLATING; CALCIUM; HUMANS; MAGNESIUM; NEUROLOGIC EXAMINATION; NEUROPROTECTIVE AGENTS; NEUROTOXICITY SYNDROMES; ORGANOPLATINUM COMPOUNDS; OUTCOME ASSESSMENT (HEALTH CARE); RESEARCH DESIGN; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 79959299866     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.34.8227     Document Type: Letter

References (15)

1. Grothey A, Nikcevich DA, Sloan JA, et al: Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin Oncol 29:421-427, 2011
2. Hochster HS, Grothey A, Childs BH: Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. J Clin Oncol 25:4028-4029, 2007 (Pubitemid 47477294)
3. Vajda FJ: Neuroprotection and neurodegenerative disease. J Clin Neurosci 9:4-8, 2002
4. Basch E, Iasonos A, McDonough T, et al: Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: Results of a questionnaire-based study. Lancet Oncol 7:903-909, 2006 (Pubitemid 44615944)
5. Cavaletti G, Frigeni B, Lanzani F, et al: The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: Comparison with the National Cancer Institute-Common Toxicity Scale. J Peripher Nerv Syst 12:210-215, 2007 (Pubitemid 47404378)
6. Park SB, Goldstein D, Lin CS, et al: Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neuropathy. J Clin Oncol 27:1243-1249, 2009
7. Park SB, Lin CS, Krishnan AV, et al: Oxaliplatin-induced neurotoxicity: Changes in axonal excitability precede development of neuropathy. Brain 132:2712-2723, 2009
8. Gamelin L, Boisdron-Celle M, Delba R, et al: Prevention of oxaliplatinrelated neurotoxicity by calcium and magnesium infusions: A retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 10:4055-4061, 2004 (Pubitemid 38812481)
9. Knijn N, Tol J, Koopman M, et al: The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients. Eur J Cancer 47:369-374, 2011
10. Grolleau F, Gamelin L, Boisdron-Celle M, et al: A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 85:2293-2297, 2001 (Pubitemid 32440704)
11. Ishibashi K, Okada N, Miyazaki T, et al: Effect of calcium and magnesium on neurotoxicity and blood platinum concentrations in patients receiving mFOLFOX6 therapy: A prospective randomized study. Int J Clin Oncol 15:82-87, 2010
12. Chay W-Y, Tan S-H, Lo Y-L, et al: Use of calcium and magnesium infusions in prevention of oxaliplatin induced sensory neuropathy. Asia Pac J Clin Oncol 6:270-277, 2010
13. Land SR, Kopec JA, Cecchini RS, et al: Neurotoxicity from oxaliplatin combined with weekly bolus Fluorouracil and Leucovorin as surgical adjuvant chemotherapy for Stage II and III colon cancer: NSABP C-07. J Clin Oncol 25:2205-2211, 2007 (Pubitemid 46954644)
14. Pietrangeli A, Leandri M, Terzoli E, et al: Persistence of high-dose oxaliplatin-induced neuropathy at long-term follow-up. Eur Neurol 56:13-16, 2006 (Pubitemid 44359537)
15. Park SB, Lin CS, Krishnan AV, et al: Long-term neuropathy after oxaliplatin treatment: Challenging the dictum of reversibility. Oncologist [Epub ahead of print on April 8, 2011]